Evaluation of event-free survival as a surrogate for overall survival in early-stage triple-negative breast cancer following neoadjuvant therapy

Fasching P, Huang M, Haiderali A, Xue W, Pan W, Karantza V, Yang F, Truscott J, Xin Y, O'Shaughnessy J (2022)

Publication Type: Conference contribution

Publication year: 2022

Journal

Annals of Oncology Elsevier

Publisher: ELSEVIER

City/Town: AMSTERDAM

Pages Range: S621-S621

Conference Proceedings Title: ANNALS OF ONCOLOGY

Event location: , ELECTR NETWORK

DOI: 10.1016/j.annonc.2022.07.221

Authors with CRIS profile

Peter Fasching Professur für Translationale Frauenheilkunde und Geburtshilfe

Involved external institutions

Merck & Co., Inc. / Merck Sharp & Dohme Corp (MSD) US United States (USA) (US) Analysis Group Ltd GB United Kingdom (GB) Texas Oncology US United States (USA) (US)

How to cite

APA:

Fasching, P., Huang, M., Haiderali, A., Xue, W., Pan, W., Karantza, V.,... O'Shaughnessy, J. (2022). Evaluation of event-free survival as a surrogate for overall survival in early-stage triple-negative breast cancer following neoadjuvant therapy. In ANNALS OF ONCOLOGY (pp. S621-S621). , ELECTR NETWORK: AMSTERDAM: ELSEVIER.

MLA:

Fasching, Peter, et al. "Evaluation of event-free survival as a surrogate for overall survival in early-stage triple-negative breast cancer following neoadjuvant therapy." Proceedings of the Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), , ELECTR NETWORK AMSTERDAM: ELSEVIER, 2022. S621-S621.

BibTeX: Download